Last update 01 Nov 2024
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.

Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.

Public Company|
1994|
Jiangsu Sheng, China
|
1,000-5,000
| SHA: 600200|
www.600200.com

Overview

Tags

Skin and Musculoskeletal Diseases
Neoplasms
Other Diseases
Small molecule drug
Herbal medicine
Enzyme

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease2
Neoplasms2
Infectious Diseases1
Nervous System Diseases1
Top 5 Drug TypeCount
Small molecule drug3
Herbal medicine1
Biosimilar1
Enzyme1
Top 5 TargetCount
PLG(Plasminogen)1
VDR(Vitamin D receptor)1
PI3Kα x mTORC1 x mTORC21

Related

7
Drugs associated with Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Colecalciferol
Target
VDR
Mechanism
VDR agonists
Active Org.
Italfarmaco SpAItalfarmaco SpA [+5]
Originator Org.
Abiogen Pharma SpAAbiogen Pharma SpA
Active Indication
Vitamin D Deficiency [+4]
Inactive Indication
Asthma [+6]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
CA
First Approval Date01 Jan 1985
Citicoline Sodium
Target-
Mechanism-
Active Org.
Jiangsu Wuzhong Medicine Group Co., Ltd.Jiangsu Wuzhong Medicine Group Co., Ltd.
Originator Org.
Jiangsu Wuzhong Medicine Group Co., Ltd.Jiangsu Wuzhong Medicine Group Co., Ltd.
Active Indication
Brain Injuries
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.-
First Approval Date-
Nitroxoline
Target
METAP2
Mechanism
METAP2 inhibitors [+1]
Active Org.
Asieris Pharmaceuticals Co., Ltd.Asieris Pharmaceuticals Co., Ltd. [+3]
Originator Org.
The Johns Hopkins UniversityThe Johns Hopkins University
Active Indication
Non-Muscle Invasive Bladder Neoplasms [+3]
Inactive Indication
Prostatic Cancer
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
4
Clinical Trials associated with Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
CTR20212794 / RecruitingPhase 1
YS001胶囊治疗晚期恶性实体瘤患者的开放标签、多中心、剂量递增和扩展I期临床试验
[Translation] An open-label, multicenter, dose-escalation and expansion phase I clinical trial of YS001 capsules in patients with advanced malignant solid tumors
CTR20160855 / CompletedPhase 1
重组人血管内皮抑素注射液在中国晚期实体瘤患者中单次及多次静脉滴注给药的耐受性及药代动力学研究
[Translation] Study on the tolerability and pharmacokinetics of single and multiple intravenous infusions of recombinant human endostatin injection in Chinese patients with advanced solid tumors
CTR20131255 / Active, not recruitingPhase 3
重组人血管内皮抑素注射液联合NP对照安慰剂联合NP治疗初治晚期非小细胞肺癌患者的三期临床研究
[Translation] Phase III clinical study of recombinant human endostatin injection combined with NP versus placebo combined with NP in the treatment of patients with newly diagnosed advanced non-small cell lung cancer
100 Clinical Results associated with Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Login to view more data
100 Deals associated with Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Login to view more data
100 Translational Medicine associated with Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
2
3
Approved
Other
2
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free